RC148

RC148 is an investigational agent whose form is not stated in the registry developed by RemeGen. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 20mg/kg, intravenous infusion, once every 2 weeks. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07416474 (RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)), in non-small-cell lung cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07416474, plans to enrol 574 participants with primary completion expected 2027-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.